Home Cart Sign in  
Chemical Structure| 184036-34-8 Chemical Structure| 184036-34-8

Structure of Sitaxsentan
CAS No.: 184036-34-8

Chemical Structure| 184036-34-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sitaxsentan is a selective endothelin A (ETA) receptor antagonist.

Synonyms: IPI 1040; TBC-11251

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sitaxsentan

CAS No. :184036-34-8
Formula : C18H15ClN2O6S2
M.W : 454.90
SMILES Code : O=S(C1=C(C(CC2=C(C)C=C(OCO3)C3=C2)=O)SC=C1)(NC4=C(Cl)C(C)=NO4)=O
Synonyms :
IPI 1040; TBC-11251
MDL No. :MFCD00945687

Safety of Sitaxsentan

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Sitaxsentan

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01347216 - Recruiting June 2020 Belgium ... More >> Dept. of Pneumology, University Recruiting Leuven, Belgium Contact: Marion Delcroix, MD, PhD          Principal Investigator: Marion Delcroix, MD, PhD          Germany DRK-Klinikum Köpenick Recruiting Berlin, Germany Contact: Christian Opitz, MD, PhD          Principal Investigator: Christian Opitz, MD, PhD          Lung Centre, University of Giessen Recruiting Giessen, Germany Contact: Ardeschir Ghofrani, MD, PhD          Principal Investigator: Ardeschir Ghofrani, MD          Sub-Investigator: Melanie Thamm, MD          Department of Pulmology; Hannover Medical School Recruiting Hannover, Germany Contact: Marius M Hoeper          Principal Investigator: Marius M Hoeper, MD, PhD          Sub-Investigator: Karen Olsson, MD          German Heart Centre Recruiting Munich, Germany Contact: Harald Kaemmerer, MD,. PhD          Principal Investigator: Harald Kaemmerer, MD, PhD          Ireland Mater Misericordiae Recruiting Dublin, Ireland Contact: Sean Gaine, MD, PhD          Principal Investigator: Sean Gaine, MD, PhD          Italy Department of Cardiovascular and Respiratory Sciences, University La Sapienza Recruiting Rome, Italy Contact: Dario Vizza, MD, PhD          Principal Investigator: Dario Vizza, MD, PhD          Switzerland Dept. for Rheumatology, University Hospital Recruiting Zurich, Switzerland Contact: Oliver Distler, MD, PhD          Principal Investigator: Oliver Distler, MD, PhD Less <<
NCT00995566 - Terminated(The trial was prema... More >>turely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.") Less << - Belgium ... More >> Pfizer Investigational Site Bruxelles, Belgium, 1070 Pfizer Investigational Site Leuven, Belgium, 3000 France Pfizer Investigational Site Nice, France, 06000 Germany Pfizer Investigational Site Hannover, Germany, 30625 Less <<
NCT00423592 Pulmonary Hypertension Phase 2 Completed - -
NCT00423592 - Completed - -
NCT00995566 - Terminated(The trial was prema... More >>turely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.") Less << - -
NCT01281371 - Completed - Germany ... More >> Department of Clinical Pharmacology and Pharmacoepidemiology, Medical department of the University of Heidelberg Heidelberg, Baden-Württemberg, Germany, 69120 Less <<
NCT00593905 - Unknown July 2013 United States, Pennsylvania ... More >> Allegheny General Hospital Recruiting Pittsburgh, Pennsylvania, United States, 15212 Contact: Andrea L Nowicki, BA    412-359-3653    anowicki@wpahs.org    Contact: Raymond L Benza, MD    412.359.3584    rbenza@wpahs.org    Principal Investigator: Raymond L Benza, MD Less <<
NCT00744211 - Completed - -
NCT00981968 Healthy Phase 1 Completed - United States, California ... More >> Pfizer Investigational Site Glendale, California, United States, 91206 Less <<
NCT00080457 Pulmonary Hypertension Phase 3 Completed - United States, Texas ... More >> Encysive Pharmaceuticals Houston, Texas, United States, 77401 Less <<
NCT01100736 Pulmonary Arterial Hypertensio... More >>n Vasodilation Vasoconstriction Less << Early Phase 1 Completed - United Kingdom ... More >> Clinical Research Centre, Western General Hospital Edinburgh, Scotland, United Kingdom, EH4 2XU Less <<
NCT00034307 Pulmonary Hypertension Phase 2 Phase 3 Unknown - -
NCT00744211 Heart Disease Not Applicable Completed - United States, South Carolina ... More >> Ralph H. Johnson VA Medical Center, Charleston, SC Charleston, South Carolina, United States, 29401-5799 Less <<
NCT01251848 Pulmonary Arterial Hypertensio... More >>n Less << Phase 1 Withdrawn February 2011 -
NCT00303498 Diastolic Heart Failure Phase 2 Completed - -
NCT01244620 - Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT01210443 Hypertension, Pulmonary Phase 3 Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - Japan ... More >> Pfizer Investigational Site Nagoya, Aichi, Japan Pfizer Investigational Site Shinjyuku-ku, Tokyo, Japan Less <<
NCT01204853 Hypertension, Pulmonary Phase 3 Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - Japan ... More >> Pfizer Investigational Site Nagoya, Aichi, Japan Pfizer Investigational Site Shinjyuku-ku, Tokyo, Japan Less <<
NCT01244620 Pulmonary Arterial Hypertensio... More >>n Less << Phase 1 Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - Singapore ... More >> Pfizer Investigational Site Singapore, Singapore, 188770 Less <<
NCT01445873 - Completed - -
NCT01445873 - Completed - -
NCT01210443 - Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT00838383 Cardiac Surgery Subjects ... More >> Subjects Undergoing CABG and/or Cardiac Valve Replacement Less << Phase 2 Completed - United States, Pennsylvania ... More >> Pfizer Investigational Site Philadelphia, Pennsylvania, United States, 19104 United States, South Carolina Pfizer Investigational Site Charleston, South Carolina, United States, 29425 United States, Tennessee Pfizer Investigational Site Chattanooga, Tennessee, United States, 37404 Less <<
NCT00796510 Pulmonary Arterial Hypertensio... More >>n Pulmonary Hypertension Less << Phase 3 Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury) Less << - United States, California ... More >> Pfizer Investigational Site Fountain Valley, California, United States, 92708 Romania Pfizer Investigational Site Cluj Napoca, Romania, 400 001 Ukraine Pfizer Investigational Site Kyiv, Ukraine Less <<
NCT01204853 - Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT00796666 Pulmonary Arterial Hypertensio... More >>n Pulmonary Hypertension Less << Phase 3 Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT01050491 Effect of Sitaxsentan on Airwa... More >>y Remodeling in Severe Asthma Less << Phase 2 Terminated(sitaxentan is not c... More >>ommercialized anymore) Less << - France ... More >> Clinical Investigation center 07, Hopital Bichat Paris, France, 75018 Less <<
NCT00817037 Chronic Kidney Disease ... More >> Proteinuria Blood Pressure Less << Phase 2 Unknown - United Kingdom ... More >> Clinical Research Centre, Western General Hospital Edinburgh, Scotland, United Kingdom, EH4 2XU Less <<
NCT00810732 Chronic Kidney Disease ... More >> CRD Less << Phase 2 Completed - United Kingdom ... More >> Pfizer Investigational Site Edinburgh, Scotland, United Kingdom, EH4 2XU Less <<
NCT00811018 Pulmonary Arterial Hypertensio... More >>n Less << Phase 3 Terminated(This trial was prem... More >>aturely terminated on Dec 9 2010 due to safety concerns, specifically emerging evidence of hepatic injury.) Less << - -
NCT00795639 Pulmonary Arterial Hypertensio... More >>n Pulmonary Hypertension Less << Phase 3 Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT00796510 - Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury) Less << - -
NCT00796666 - Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT01251835 Pulmonary Arterial Hypertensio... More >>n Less << Phase 1 Withdrawn January 2011 -
NCT00795639 - Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.) Less << - -
NCT00811018 - Terminated(This trial was prem... More >>aturely terminated on Dec 9 2010 due to safety concerns, specifically emerging evidence of hepatic injury.) Less << - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.20mL

0.44mL

0.22mL

10.99mL

2.20mL

1.10mL

21.98mL

4.40mL

2.20mL

References

 

Historical Records

Categories